Managing Aminotransferase Elevations in Patients with Friedreich Ataxia Treated with Omaveloxolone: A Review and Expert Opinion on Use Considerations

Managing Aminotransferase Elevations in Patients with Friedreich Ataxia Treated with Omaveloxolone: A Review and Expert Opinion on Use Considerations

Abstract Omaveloxolone is approved for the treatment of Friedreich ataxia (FA) in patients aged ≥ 16 years and is under clinical development for pediatric patients. In the MOXIe study, alanine and aspartate aminotransferase (ALT and AST) elevations were among the most common treatment-emergent adver...

Full description

Saved in:
Bibliographic Details
Main Authors: Susan Perlman, Mathieu Anheim, Sylvia Boesch, James H. Lewis, David R. Lynch
Format: Article
Language:English
Published: Adis, Springer Healthcare 2025-06-01
Series:Neurology and Therapy
Subjects:
Alanine aminotransferase (ALT)
Aspartate aminotransferase (AST)
Drug-induced liver injury (DILI)
Friedreich ataxia
Liver function test
Nuclear factor-erythroid 2-related factor 2 (Nrf2)
Online Access:https://doi.org/10.1007/s40120-025-00752-8
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1007/s40120-025-00752-8

Similar Items